ABVC BioPharma Receives $450,000 in Q3 Licensing Payments from OncoX BioPharma

ABVC BioPharma, Inc. (NASDAQ: ABVC) announced that its partner OncoX BioPharma has delivered $450,000 in licensing payments in the third quarter of 2025, including $350,000 received in August. These payments underscore the strength of the companies' strategic alliance and the growing commercial potential of ABVC's oncology pipeline. Under the licensing agreements with OncoX, ABVC is entitled to 5,000,000 OncoX shares and $2,500,000 in cash payments, plus royalties.

To date, ABVC has received $650,000 in cash (including $200,000 in 2024 and $450,000 in Q3 2025), with $1,850,000 remaining in receivable cash and its 5,000,000 OncoX shares secured. The OncoX collaboration covers four major oncology indications: Triple Negative Breast Cancer (TNBC), Non-Small Cell Lung Cancer (NSCLC), Myelodysplastic Syndromes (MDS), and Pancreatic Cancer. All four indications have received FDA IND (Investigational New Drug) approvals, demonstrating ABVC's strong development position in botanical-derived oncology drug candidates.

According to Precedence Research, the global cancer therapeutics market was valued at approximately US$194.67 billion in 2024 and is projected to expand to US$469.38 billion by 2034, growing at a CAGR of 9.2%. These figures highlight the substantial commercial opportunity for ABVC through their partnership with OncoX. Dr. Uttam Patil, ABVC's Chief Executive Officer, stated that the $450,000 received demonstrates the execution strength of their collaboration and highlights both immediate liquidity and long-term equity value.

This licensing partnership with OncoX strengthens ABVC's strategic positioning in oncology by combining immediate and potential cash inflows, equity holdings, and future royalty streams, creating a framework with a consolidated value exceeding $41 million (excluding royalties). The collaboration further cements ABVC's leadership in advancing botanical-derived oncology therapeutics toward global commercialization in a market that continues to show significant growth potential according to industry research available at synapse.patsnap.com.